€42.20 BIO.DE (Biotest AG XETRA) pre-market: Oversold bounce may reach €44.50
BIO.DE stock trades at €42.20 pre-market on 22 Jan 2026, following a small pullback from the year high. The move leaves Biotest AG (BIO.DE) on XETRA in a classic oversold bounce setup with light volume (175.00 shares traded) and price clustered near the 50-day average. We see a low-risk trade window if buyers push above €43.00, with immediate resistance at €43.20 and support at €40.40.
Pre-market snapshot for BIO.DE stock
Biotest AG (BIO.DE) opened pre-market at €42.20 on XETRA in Germany. Intraday range shows a day low €42.20 and day high €43.00 today. Volume is light at 175.00 versus an average of 129.00, giving the price move room to accelerate if buyers step in.
Why BIO.DE stock looks set for an oversold bounce
Price sits slightly below the 50-day average of €42.54 and above the 200-day average of €41.71, a profile that often precedes short-term bounces. The stock shows limited downside to the year low at €40.40, which makes a measured long position for a bounce attractive to traders. Sector momentum in Healthcare is muted, so strength will likely come from company-specific flows.
Technical levels, triggers and price targets for BIO.DE stock
Key levels: support €40.40, immediate resistance €43.20, breakout level €44.50, and a cautious target at €48.00. The 50-day average at €42.54 is the first gate for bulls. A close above €44.50 on rising volume would validate a larger retracement toward €48.00.
Fundamentals and valuation context for BIO.DE stock
Biotest reports EPS -0.63 and a trailing PE of -66.98, reflecting negative earnings. Price-to-sales sits at 2.92 and price-to-book at 3.22. The company has a strong current ratio of 4.93, but cash flow metrics are weak. These fundamentals make gains dependent on operational improvement or positive news.
Meyka AI rates BIO.DE with a score out of 100 and model forecast
Meyka AI rates BIO.DE with a score out of 100: 66.83 | Grade B | Suggestion: HOLD. This grade factors S&P 500 and sector comparisons, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a 12-month value of €42.05, implying -0.36% vs current €42.20. Forecasts are model-based projections and not guarantees.
Trading strategy, risk controls and sector note for BIO.DE stock
For an oversold bounce trade, buy near €42.20 with a tight stop under €40.80 and a first take-profit at €44.50. Position size should limit risk to 1.0%–2.0% of portfolio value. Healthcare sector volatility is moderate; watch news and volume. Use a trailing stop if price clears €44.50.
Final Thoughts
BIO.DE stock offers a short-term oversold bounce setup in pre-market on 22 Jan 2026. The stock trades at €42.20 on XETRA with low volume (175.00) and clear technical gates: support €40.40 and resistance €43.20. Meyka AI’s forecast model projects €42.05 over 12 months, an implied change of -0.36% versus the current price. Traders can look for a bounce above the 50-day average €42.54 and use €44.50 as the first target. Maintain strict stops under €40.80 and limit exposure given negative EPS (-0.63) and mixed cash flow metrics. This analysis uses Meyka AI’s real-time tools and public filings. Forecasts are model-based projections and not guarantees.
FAQs
What is the current price and setup for BIO.DE stock?
BIO.DE stock is at €42.20 pre-market on 22 Jan 2026. The setup is an oversold bounce with low volume and immediate resistance at €43.20 and support at €40.40.
How does Meyka AI view BIO.DE stock?
Meyka AI rates BIO.DE with a score out of 100: 66.83 (Grade B, HOLD). The grade weighs benchmark and sector comparisons, growth, metrics, forecasts, and consensus.
What price targets and stops suit a BIO.DE stock bounce trade?
Target €44.50 for an initial bounce and €48.00 if volume confirms the break. Use a stop under €40.80 and size positions to limit portfolio risk to 1.0%–2.0%.
What fundamental risks affect BIO.DE stock?
Key risks include negative EPS (-0.63), weak cash flow ratios, and inventory cycles. Biotest’s leverage and margins can widen volatility in the Healthcare sector.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
